Valeant Pharmaceuticals International Inc

Valeant Pharmaceuticals International — Technical Presentation (February 2008)

16 slides from Valeant Pharmaceuticals International's technical presentation, Feb 14, 2008

  1. Slide 1: RESTORE 1 Summary Results

    RESTORE 1 Summary Results February 14, 2008

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding expectations or plans of the company's Phase III program for retigabine and the potential role retigabine could play in managing epilepsy. These statements are based

  3. Slide 3: Agenda

    Agenda Comments from M. Pearson Presentation from Dr. H. Mansbach, M.D. Q&A guidelines Discussion on RESTORE 1 results only No updated commercial or market guidance Management is still in a quiet period Earnings Call on Feb. 28

  4. Slide 4: RESTORE 1 Summary Results

    RESTORE 1 Summary Results February 14, 2008

  5. Slide 5: Retigabine

    Retigabine A first-in-class neuronal potassium channel opener in late Phase III clinical development A novel mechanism of action A promising approach to treatment of epilepsy and other CNS diseases

  6. Slide 6: Retigabine Clinical Program

    Retigabine Clinical Program Comprehensive phase I and II clinical program Positive, published* results from Study 205, the retigabine Phase IIb trial in epilepsy Tested 600, 900, and 1200 mg doses RESTORE 1 results available now RESTORE 2 results available 2Q2008 Anticipate submitting to the US and

  7. Slide 7: RESTORE Trials: Overview

    RESTORE Trials: Overview Pair of Phase III studies with similar design Randomized, double-blind, placebo-controlled Adult epilepsy patients with refractory partial-onset seizures on a stable regimen of 1 - 3 background anti-epileptic drugs (AEDs) Primary endpoints and study design appropriate to mee

  8. Slide 8: Primary Efficacy Endpoints

    Primary Efficacy Endpoints FDA Submission Median reduction in total partial-seizure frequency per 28 days from baseline to the end of the double-blind period EMEA* Submission Proportion of responders (>50% reduction in seizure frequency per 28 days comparing maintenance period to baseline) *EMEA = E

  9. Slide 9: RESTORE Study Design

    RESTORE 1 Study Design 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Baseline Phase (8 weeks) Titration Phase (6 weeks) Maintenance Phase (12 weeks) 18-Week Double-Blind Phase Retigabine 1050 mg/day Retigabine 1200 mg/day Randomization Start Retigabine 300 mg/day (increase by 150

  10. Slide 10: Patient Disposition

    Patient Disposition **ITT = all subjects who took at least 1 dose of study medication and had at least 1 efficacy evaluation Data on file. Valeant Pharmaceuticals International. *Safety = all subjects who took at least 1 dose of study medication

  11. Slide 11: Summary Patient Characteristics

    Summary Patient Characteristics CGI= Clinician's Global Impression Data on file. Valeant Pharmaceuticals International. Safety population

  12. Slide 12: Primary Endpoint Results: FDA Endpoint

    Primary Endpoint Results: FDA Endpoint Median Reduction (%) ITT population Median reduction in 28-day total partial seizure frequency Data on file. Valeant Pharmaceuticals International. *p <0.0001 FDA endpoint N=150 N=119 N=151 N=137 N=150 N=151 * * *

  13. Slide 13: Primary Endpoint Results: CHMP Endpoint for EMEA submission

    Primary Endpoint Results: CHMP† Endpoint for EMEA submission Patients (%) *p <0.0001 Responder Rate: ^50% decrease in 28-day total partial seizure frequency ITT population †CHMP = European Union Committee for Human Medicinal Products Data on file. Valeant Pharmaceuticals International. CHMP endpoint

  14. Slide 14: Treatment-Emergent Adverse Events in RESTORE

    Treatment-Emergent Adverse Events in RESTORE 1 (^ 10% incidence) Safety population Data on file. Valeant Pharmaceuticals International.

  15. Slide 15: Conclusions

    Conclusions Retigabine 1200 mg was statistically superior to placebo (p<0.0001) on primary endpoints for FDA and CHMP regulatory review Results confirm potential utility of neuronal potassium openers in epilepsy Generally well-tolerated RESTORE 2 results expected in 2Q2008 On track for submission to

  16. Slide 16: RESTORE 1 Summary Results

    RESTORE 1 Summary Results February 14, 2008

Valeant Pharmaceuticals International — Technical Presentation (February 2008) on 6ix